News
| 4 min read
Discover how ubrogepant provides migraine relief during the prodrome phase, easing symptoms before headaches fully develop.
| 3 min read
Clinical trials rigorously test treatments to further scientific knowledge and benefit patients. Neither happens if the results are never published.
| 4 min read
The Bethesda Declaration, a new RSV antibody for kids, amylin’s promising weight loss results, and more were industry’s need-to-know stories this week.
| 9 min read
With new insight into IgE biology, a new, two-pronged strategy for eliminating the pathogenic immune cells that lead to allergies emerges.
| 6 min read
Via a unique regulatory route in the UK, scientists found that a gene therapy restored vision in young kids with a very rare and severe retinal dystrophy.
| 4 min read
By identifying high-risk pregnancies early, Mirvie’s new RNA-based test opens the door to timely prevention.
| 5 min read
Promising small cell lung cancer results, COVID-19 vaccine confusion, billion-dollar deals, and more led the news this week.
| 2 min read
Plummeting blood sugar can accelerate eye damage due to diabetes. Results in mice suggest that a new drug targeting hypoxia inducible factor could help.
| 6 min read
Rather than permanently cutting DNA, this new kind of gene therapy instead aims to regulate gene expression using epigenetic mechanisms.
| 4 min read
A novel immunotherapy targets the liver to promote tolerance to allergens in mice, promising durable allergy relief without the risk of severe reactions.
| 4 min read
HHS decisions on COVID-19 and flu vaccines, new therapies with encouraging results for depression and ALS, and more industry news this week.
| 6 min read
Larkspur Biosciences scientists develop drugs that make colorectal cancer tumors vulnerable to killing by the immune system and cell death pathways.
